bosutinib

Pharma company publishes a list of 17 companies known to have sold the incorrect isomer of the kinase inhibitor bosutinib.

An incorrect isomer of the kinase inhibitor bosutinib is circulating in the biomedical research community, potentially throwing doubt on study results.